Management Quality -- 6/10
DexCom management scores a 6/10 -- the lowest dimension -- reflecting a genuine post-crisis recovery
that has not yet fully restored trust. The Q2 2024 guide-down (~$250M midpoint cut, stock down ~40%)
was entirely self-inflicted from a botched salesforce expansion and DME channel neglect. Since then,
8 of 10 verifiable promises have been met, US organic growth recovered from -2% to +21%, and revenue
hit $4.66B in FY2025 (above initial $4.6B target). However, the gross margin guide was clearly missed
(64-65% guided, ~61% delivered), and a CEO transition is underway with Jake Leach (20-year insider,
former CTO) replacing Kevin Sayer in January 2026. Trust is recovering but the burden of proof remains.
Weight: 20%
CEO
Jake Leach (Jan 2026)
20yr insider, former CTO/EVP | Unproven as public-co CEO
Promise Delivery
8/10 = 80%
1 clear miss (gross margin), 1 mostly met (15-day timing)
Q2 2024 Trust Event
~$250M guide-down
Self-inflicted: botched salesforce expansion, stock -40%
FY2025 Revenue
$4.66B (beat guide)
Initial $4.6B target exceeded; organic growth 3% to 20%
Leadership team
Jake Leach -- President and CEO (Jan 2026)
20+ years at DexCom. Former CTO/EVP, promoted to President May 2025, CEO January 2026.
Deep institutional and technical knowledge -- led the G7 and Stelo product development.
Unproven as a public company CEO and capital allocator. The key question is whether
technical excellence translates to commercial and financial leadership. Inherits a
recovering business with momentum but unfinished trust restoration.
Kevin Sayer -- Chairman, former CEO (2014-2025)
Built DexCom from ~$400M to ~$4.7B revenue over ~12 years as CEO. Oversaw both the
Q2 2024 guide-down debacle and the initial recovery. Took medical leave in Q3 2025,
stepped down end of 2025. Long successful tenure but departure timing -- after recovery
but before the next growth phase is fully proven -- raises questions. Took direct control
of the sales organization after CCO Lawver departed in Q3 2024.
Jereme Sylvain -- CFO (since 2022)
Solid operator and clear communicator on calls. Managed guidance through the volatile
post-guide-down period. Provides detailed financial breakdowns on quarterly calls.
Navigated a difficult stretch of supply chain disruptions and margin compression with
transparency about the issues and recovery trajectory.
Teri Lawver -- Former CCO (retired Q3 2024)
Departed amid the commercial execution failures that caused the Q2 2024 guide-down.
Her retirement announcement at Q3 2024 -- right when the commercial strategy was
failing -- raised questions about accountability. Sayer took direct control of the
sales organization after her departure.
Promise vs. delivery tracker (10 resolved, 1 pending)
| When Promised | Promise | Evidence | Grade |
|---|---|---|---|
| Q3 2024 | Revenue recovery to $4.6B in 2025 | FY2025 actual = $4.662B; guided $4.6B initially, raised to $4.63-$4.65B. Delivered above target. | MET |
| Q3-Q4 2024 | US growth recovery | US organic growth: Q3 2024 -2%, Q4 +4%, Q1 2025 +15%, Q2 +15%, Q3 +21%, Q4 +11%. Clear recovery. | MET |
| Q3 2024 | Record new patient starts sustained | Record starts reported in Q4 2024, Q1 2025, Q2 2025. Confirmed across multiple quarters. | MET |
| Q4 2024+ | Stelo 2-3% of revenue in FY2025 | Surpassed $100M in first 12 months (Q3 2025). 2-3% of ~$4.66B = ~$93-$140M. On track. | MET |
| Q4 2024 | Non-GAAP operating margin ~21% in 2025 | FY2025 non-GAAP op income $969M on $4,662M revenue = 20.8%. Very close to 21% target. | MET (approx) |
| Q4 2024 | Gross margin 64-65% in 2025 | Guided DOWN to ~62% at Q1 2025 due to supply chain/freight. FY2025 blended ~61%. Missed by ~300bps. | MISSED |
| Q4 2024 | G7 15-day launch H2 2025 | FDA clearance by Q2 2025. Limited launch Q3 2025. Broad rollout Jan 2026. Slightly delayed. | MOSTLY MET |
| Q3 2024+ | International growth acceleration | Intl organic growth: +16%, +19%, +12%, +14%, +18%, +15%. Consistently solid. | MET |
| Q3 2024 | DME share stabilization | Q4 2024: DME share remained stable. Confirmed throughout 2025. | MET |
| Q4 2024+ | Type 2 non-insulin coverage: 5M+ lives, 3 largest PBMs | 2 of 3 PBMs by Jan 2025, 3rd by July 2025. ~6M non-insulin lives by end of 2025. | MET |
10 resolved promises tracked -- 8 met, 1 mostly met (15-day timing), 1 missed (gross margin).
FY2026 guidance ($5.16-$5.25B revenue, 22-23% op margin) pending next earnings. The gross margin
miss is notable: management guided 64-65% at Q4 2024 then cut to ~62% just one quarter later,
delivering ~61% blended. This pattern of operational surprise echoes the Q2 2024 debacle.
Source: Daloopa, earnings call transcripts Q3 2024 - Q4 2025.
Post-guide-down financial recovery (Q3 2024 - Q4 2025)
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|
| Revenue ($M) | $994 | $1,114 | $1,036 | $1,157 | $1,209 | $1,260 |
| Organic Growth | 3% | 8% | 14% | 15% | 20% | 12% |
| US Organic Growth | -2% | +4% | +15% | +15% | +21% | +11% |
| Non-GAAP Gross Margin | 63.0% | 59.4% | 57.5% | 60.1% | 61.3% | 63.5% |
| Non-GAAP Op Margin | 21.3% | 18.8% | 13.8% | 19.2% | 22.6% | 26.3% |
| Non-GAAP EPS | $0.45 | $0.45 | $0.32 | $0.48 | $0.61 | $0.68 |
Revenue recovery from the Q2 2024 trough has been strong -- organic growth peaked at 20% in Q3 2025.
Gross margin troughed at 57.5% in Q1 2025 (supply chain disruptions) but recovered to 63.5% by Q4 2025.
Non-GAAP EPS trajectory from $0.45 to $0.68 demonstrates significant earnings power recovery.
Capital allocation assessment
Convertible settlement -- disciplined
Settled $1.2B convertible notes in cash -- avoided dilution and demonstrated balance sheet
strength. Smart use of capital that protected shareholders from equity dilution at a time
when the stock was under significant pressure post-guide-down.
Share repurchases -- $750M+
Executed $750M+ in share buybacks, taking advantage of depressed valuation post-Q2 2024.
Crossed $1B in free cash flow for the first time in FY2025. Repurchases at depressed
prices are a strong signal of management conviction in the recovery thesis.
Product investment -- Stelo and G7 15-day
Stelo OTC surpassed $100M in its first 12 months -- on track for 2-3% of FY2025 revenue.
G7 15-day sensor received FDA clearance and began broad US rollout in January 2026.
Both products expand the addressable market and reduce sensor change burden. R&D
investment continues to be a core strength.
Free cash flow milestone
Crossed $1B in free cash flow for the first time in FY2025. Strong cash generation
supports both product investment and shareholder returns. Balance sheet is healthy
with no acute leverage concerns.
Strengths and concerns
Strengths
1. Revenue recovery is real. US organic growth went from -2% in Q3 2024 to
+21% in Q3 2025. FY2025 revenue of $4.66B exceeded the initial $4.6B recovery target.
New patient starts hit record levels across multiple consecutive quarters.
2. 8 of 10 promises delivered. Post-crisis promise delivery rate of 80% demonstrates that management can execute when focused. Revenue, US growth, Stelo ramp, DME stabilization, and type 2 coverage all tracked to commitments.
3. Capital allocation discipline. $1.2B convert settled in cash. $750M+ in buybacks at depressed prices. Crossed $1B FCF for the first time. Smart balance sheet management through a difficult period.
4. Product pipeline executing. Stelo surpassed $100M in first 12 months. G7 15-day sensor cleared FDA and launched. International growth consistently +12-19%. The innovation engine remains intact despite commercial missteps.
5. Type 2 expansion progressing. ~6M non-insulin lives covered by end of 2025. All 3 largest PBMs onboarded. Structural TAM expansion is real even if timeline is aggressive.
2. 8 of 10 promises delivered. Post-crisis promise delivery rate of 80% demonstrates that management can execute when focused. Revenue, US growth, Stelo ramp, DME stabilization, and type 2 coverage all tracked to commitments.
3. Capital allocation discipline. $1.2B convert settled in cash. $750M+ in buybacks at depressed prices. Crossed $1B FCF for the first time. Smart balance sheet management through a difficult period.
4. Product pipeline executing. Stelo surpassed $100M in first 12 months. G7 15-day sensor cleared FDA and launched. International growth consistently +12-19%. The innovation engine remains intact despite commercial missteps.
5. Type 2 expansion progressing. ~6M non-insulin lives covered by end of 2025. All 3 largest PBMs onboarded. Structural TAM expansion is real even if timeline is aggressive.
Concerns
1. Q2 2024 guide-down was Category 5. A ~$250M midpoint revenue cut from
entirely self-inflicted commercial execution failures. Stock fell ~40% in one day. This
cannot be erased by 6 quarters of recovery -- it revealed blind spots in core CEO
competencies (channel management, salesforce execution).
2. Gross margin guide clearly missed. Guided 64-65% at Q4 2024, delivered ~61% blended for FY2025. The guide was cut to ~62% just one quarter later at Q1 2025. This is a second operational surprise in a short period, even if driven by different factors (supply chain vs. commercial).
3. CEO transition adds uncertainty. Leach is a 20-year insider with deep technical knowledge but zero track record as a public company CEO or capital allocator. Sayer departed after starting the recovery but before fully proving it out. Medical leave in Q3 2025 further complicated optics.
4. CCO departure during crisis. Lawver retired at Q3 2024 right when the commercial strategy was failing. Accountability questions linger around the salesforce expansion that caused the guide-down.
5. Market has not forgiven. Stock remains well below pre-guide-down levels ($160+ then vs. ~$62 now), suggesting investors still carry a significant trust discount.
2. Gross margin guide clearly missed. Guided 64-65% at Q4 2024, delivered ~61% blended for FY2025. The guide was cut to ~62% just one quarter later at Q1 2025. This is a second operational surprise in a short period, even if driven by different factors (supply chain vs. commercial).
3. CEO transition adds uncertainty. Leach is a 20-year insider with deep technical knowledge but zero track record as a public company CEO or capital allocator. Sayer departed after starting the recovery but before fully proving it out. Medical leave in Q3 2025 further complicated optics.
4. CCO departure during crisis. Lawver retired at Q3 2024 right when the commercial strategy was failing. Accountability questions linger around the salesforce expansion that caused the guide-down.
5. Market has not forgiven. Stock remains well below pre-guide-down levels ($160+ then vs. ~$62 now), suggesting investors still carry a significant trust discount.
Red flags check
| Flag | Severity | Detail |
|---|---|---|
| Q2 2024 guidance cut | MAJOR | ~$250M guide-down, entirely self-inflicted from botched salesforce expansion and DME neglect |
| CCO departure during crisis | Moderate | Lawver retired Q3 2024 amid commercial execution failures; accountability questions remain |
| CEO transition | Moderate | Sayer departed end of 2025; Leach is technically strong but unproven as public-co CEO |
| Supply chain disruptions | Moderate | Damaged sensor shipment Q4 2024 led to ~300bps gross margin compression persisting 3 quarters |
| Gross margin guide-down | Notable | Guided 64-65%, cut to ~62% one quarter later, delivered ~61%. Second operational surprise. |
| TAM narrative aggression | Minor | 25M type 2 non-insulin cited as addressable but current coverage only ~6M; directionally correct but aggressive |
| Capital allocation | Positive | Settled $1.2B convert in cash, $750M+ buybacks, crossed $1B FCF in FY2025 |
| Board/insider activity | Neutral | No unusual insider selling flagged; board approved orderly CEO succession |
Score rationale
6/10. This is the lowest dimension score, reflecting genuine recovery from the Q2 2024
guide-down that has not yet fully restored trust. Revenue growth reaccelerated dramatically (3% organic
to 20%), 8 of 10 promises have been delivered, US growth recovered from -2% to +21%, and capital
allocation has been disciplined ($1.2B convert settled in cash, $750M+ buybacks, $1B+ FCF). The
recovery trajectory is real and impressive.
Why not 7+: (1) The Q2 2024 guide-down was a top-tier credibility destroyer -- ~$250M self-inflicted from botched salesforce expansion, stock down 40% in a day; (2) gross margin was clearly missed in 2025 (64-65% guided, ~61% delivered), adding a second data point of operational surprise; (3) CEO transition underway with Leach unproven as a public company CEO; (4) CCO departed during the crisis with unresolved accountability questions; (5) stock remains well below pre-guide-down levels, indicating the market has not forgiven.
What would move this to 7+: Leach demonstrates 2-3 quarters of clean execution as CEO with no guidance revisions. Gross margins recover to 64%+ sustained. FY2026 guidance ($5.16-$5.25B revenue, 22-23% op margin) is met or exceeded without mid-year cuts. No further operational surprises (supply chain, commercial execution). The trust deficit requires time and consistency to close -- the burden of proof remains on this team.
Why not 7+: (1) The Q2 2024 guide-down was a top-tier credibility destroyer -- ~$250M self-inflicted from botched salesforce expansion, stock down 40% in a day; (2) gross margin was clearly missed in 2025 (64-65% guided, ~61% delivered), adding a second data point of operational surprise; (3) CEO transition underway with Leach unproven as a public company CEO; (4) CCO departed during the crisis with unresolved accountability questions; (5) stock remains well below pre-guide-down levels, indicating the market has not forgiven.
What would move this to 7+: Leach demonstrates 2-3 quarters of clean execution as CEO with no guidance revisions. Gross margins recover to 64%+ sustained. FY2026 guidance ($5.16-$5.25B revenue, 22-23% op margin) is met or exceeded without mid-year cuts. No further operational surprises (supply chain, commercial execution). The trust deficit requires time and consistency to close -- the burden of proof remains on this team.
Data sourced from Daloopa and earnings call transcripts Q3 2024 - Q4 2025.